Ionis Pharmaceuticals Inc (NASDAQ:IONS) has been assigned a consensus rating of “Hold” from the seventeen analysts that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $49.90.
IONS has been the subject of a number of recent research reports. BidaskClub upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, December 7th. Needham & Company LLC reiterated a “buy” rating and set a $64.00 price objective on shares of Ionis Pharmaceuticals in a research note on Tuesday, October 17th. Morgan Stanley lifted their price objective on Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 8th. Barclays reduced their price objective on Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating for the company in a research note on Thursday, September 21st. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $50.00 price objective on shares of Ionis Pharmaceuticals in a research note on Friday, October 13th.
In other news, Chairman Stanley T. Crooke sold 16,549 shares of the firm’s stock in a transaction dated Monday, January 15th. The stock was sold at an average price of $51.76, for a total transaction of $856,576.24. Following the sale, the chairman now directly owns 67,626 shares in the company, valued at approximately $3,500,321.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Elizabeth L. Hougen sold 2,724 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $51.76, for a total value of $140,994.24. Following the sale, the chief financial officer now owns 17,224 shares in the company, valued at $891,514.24. The disclosure for this sale can be found here. Insiders have sold a total of 107,385 shares of company stock worth $5,596,041 over the last 90 days. Insiders own 2.13% of the company’s stock.
Several large investors have recently bought and sold shares of IONS. Vanguard Group Inc. grew its position in shares of Ionis Pharmaceuticals by 4.4% during the 2nd quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock valued at $501,332,000 after acquiring an additional 417,364 shares during the period. American Century Companies Inc. boosted its holdings in Ionis Pharmaceuticals by 33.0% in the 3rd quarter. American Century Companies Inc. now owns 1,144,526 shares of the company’s stock worth $58,027,000 after buying an additional 284,266 shares during the last quarter. First Trust Advisors LP boosted its holdings in Ionis Pharmaceuticals by 40.2% in the 3rd quarter. First Trust Advisors LP now owns 982,344 shares of the company’s stock worth $49,805,000 after buying an additional 281,733 shares during the last quarter. BlackRock Inc. boosted its holdings in Ionis Pharmaceuticals by 4.0% in the 2nd quarter. BlackRock Inc. now owns 6,823,987 shares of the company’s stock worth $347,135,000 after buying an additional 264,179 shares during the last quarter. Finally, AXA acquired a new stake in Ionis Pharmaceuticals in the 3rd quarter worth about $5,202,000. Hedge funds and other institutional investors own 91.40% of the company’s stock.
Ionis Pharmaceuticals (NASDAQ:IONS) traded down $1.92 during midday trading on Monday, hitting $49.69. The company’s stock had a trading volume of 748,480 shares, compared to its average volume of 862,504. The stock has a market cap of $6,180.00, a price-to-earnings ratio of 354.93 and a beta of 2.86. Ionis Pharmaceuticals has a twelve month low of $37.26 and a twelve month high of $65.51. The company has a debt-to-equity ratio of 1.50, a current ratio of 6.25 and a quick ratio of 6.21.
ILLEGAL ACTIVITY NOTICE: “Ionis Pharmaceuticals Inc (IONS) Receives $49.90 Average Target Price from Brokerages” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/18/ionis-pharmaceuticals-inc-ions-receives-49-90-average-target-price-from-brokerages.html.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.